Training activity information
Details
Interpret assays for the analysis for Methotrexate, Digoxin and one of the following:
- Phenytoin,
- Theophylline,
- Gentamicin,
- Vancomycin,
Type
Entrustable training activity (ETA)
Evidence requirements
Evidence the activity has been undertaken by the trainee repeatedly, consistently, and effectively over time, in a range of situations. This may include occasions where the trainee has not successfully achieved the outcome of the activity themselves. For example, because it was not appropriate to undertake the task in the circumstances or the trainees recognised their own limitations and sought help or advice to ensure the activity reached an appropriate conclusion.
Reflection at multiple timepoints on the trainee learning journey for this activity.
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
What does success look like?
- What is expected of you in relation to successfully interpreting the assays for methotrexate, digoxin, and your third chosen drug according to laboratory SOPs?
- How will you demonstrate that you have met the specific learning outcomes, such as analysing drugs in various matrices and applying pharmacokinetic principles for Therapeutic Drug Monitoring (TDM)?
- Have you discussed with your training officer to gain clarity on the expected depth of interpretation required, including the importance of sampling times and sample types?
- How will you ensure your interpretation provides an appropriate investigative strategy and actionable advice for clinical teams?
What is your prior experience of this activity?
- What do you already know about the pharmacokinetics, therapeutic ranges, and toxicity of methotrexate, digoxin, and your third chosen medication?
- What challenges do you anticipate facing, such as interpreting results in patients with a complex history or unclear sample timing?
- Are you clear on the scope of your practice? Do you know exactly when and from whom you should seek advice—for example, if an interpretation requires confirmation regarding multi-organ failure or suspected drug interactions?
- How do you feel about embarking on the interpretation of these specific medication assays, particularly those with narrow therapeutic windows?
What do you anticipate you will learn from the experience?
- What insights do you hope to gain into the practical application of pharmacokinetics and pharmacogenomics for achieving optimal drug levels in clinical practice?
- How will this activity improve your understanding of the legal consequences of drug testing and how toxicology results are used within various clinical settings?
What additional considerations do you need to make?
- Have you consulted any actions or improvements identified from your previous experiences of interpreting results that required clinical correlation?
- What critical information must you review before starting, such as the specific SOPs for the chosen assays, the clinical indications for TDM, and the pre-analytical requirements to confirm appropriate sample collection?
- How have you prepared to evaluate the legal and clinical significance of these results as they pertain to current national guidelines?
In action
During the activity did anything unexpected occur?
- Are you noticing anything surprising or different from what you anticipated while performing the initial interpretation for these therapeutic drugs?
- Are you encountering situations such as:
- An analyser error or unexpected Quality Control (QC) result that occurs while you are trying to validate a methotrexate or phenytoin run?
- A digoxin or theophylline level that is significantly outside the therapeutic range and conflicts with the documented sample timing or patient monitoring protocol?
- A result that appears inconsistent with the patient’s clinical history, suggesting potential assay interference or a pre-analytical error?
- How does this specific interpretation compare with previous experiences, particularly regarding the criticality of sampling times for drugs with narrow therapeutic windows?
How did you react to the unexpected development?
- How is the unexpected result impacting your actions; for example, are you questioning the sample integrity or timing for a discordant digoxin level?
- Consider the steps you are taking in the moment to ensure analytical and clinical accuracy, such as:
- Immediately halting the interpretation to consult the Standard Operating Procedure (SOP) or troubleshoot the method.
- Applying pharmacokinetic principles to determine if the result is physiologically plausible given the dose and time since administration.
- Reviewing the patient’s renal or liver function to see if it explains an unexpectedly high drug level (e.g., Vancomycin or Theophylline).
- How are you feeling in that moment; for instance, are you finding it difficult to adapt your interpretation due to poor sample timing, and is it affecting your confidence to work independently?
What was the conclusion or outcome?
- How are you identifying whether you are working within your scope of practice? For example, do you need support because the complex pharmacokinetics of a drug in a patient with multi-organ failure requires senior interpretation?
- What are you learning in real-time about the clinical consequences of drug testing, particularly when results may lead to significant changes in patient management or have toxicology implications?
- Are you gaining a deeper insight into how pre-analytical errors—such as sampling before reaching a steady state—can lead to misleading biochemical data?
- If a result is critical or suggests toxicity, are you following the correct escalation pathways to provide immediate advice to the clinical team?
On action
What happened?
- How would you summarise the key points of the experience, specifically regarding the interpretation of methotrexate, digoxin, and your third chosen drug (e.g., gentamicin or vancomycin)?
- Which specific events or interactions felt important, such as applying your knowledge of sample timing (e.g., trough levels) during the interpretation process?
- How did you feel during the experience—did you feel confident applying the laboratory Standard Operating Procedures (SOPs) or stressed by interpreting results that were significantly outside the therapeutic range?
- What ‘reflect-in-action’ moments did you record, such as the need to question sample validity due to an unusually high digoxin level?
How has this experience contributed to your developing practice?
- What specific learning have you gained regarding analysing drugs in various matrices and applying pharmacokinetic principles?
- What strengths did you demonstrate, such as a strong understanding of steady-state kinetics?
- What knowledge gaps were identified, such as unfamiliarity with the influence of drug interactions or the specific units used for methotrexate reporting?
- How did you handle the challenges of the activity, particularly if you needed to seek advice or escalate a case because the complex pharmacokinetics in a patient with multi-organ failure exceeded your current scope of practice?
- Looking back now, has your understanding of the relationship between analytical results and clinical toxicology/TDM scenarios improved compared to previous activities?
What will you take from the experience moving forward?
- What ‘next steps’ will you take to support the assimilation of what you have learned, such as reviewing feedback from your training officer regarding your investigative strategies?
- What will you do differently next time you approach a complex TDM interpretation, for instance, by proactively reviewing the specific methodology or the legal consequences of toxicology results?
- Do you need to practise any specific aspect of the activity further, such as interpreting TDM results across a wider range of diverse clinical scenarios?
- How has this experience shaped your ability to advise clinical teams on the appropriate course of action for patients with suspected drug toxicity?
Beyond action
Have you revisited the experiences?
- How have your subsequent experiences of performing Therapeutic Drug Monitoring (TDM) assays and applying pharmacokinetic principles led you to evaluate and re-evaluate your initial approach to this activity?
- Have you reviewed the actions from your previous reflections, such as the need to integrate specific criteria for assessing steady-state kinetics when interpreting methotrexate results?
- How has professional storytelling with senior colleagues regarding overdose cases or pre-analytical timing errors (e.g., a poorly timed digoxin sample) refined your understanding of the critical nature of pre-analytical verification in TDM?
- Are you now ready to demonstrate this new learning in practice to ensure you are accurately analysing drugs in various biological matrices?
How have these experiences impacted upon current practice?
- How has the learning from this initial activity, combined with subsequent TDM experiences, contributed to your overall confidence and competence in preparing for assessments such as Direct Observations of Practical Skills (DOPS) or Case-Based Discussions (CBDs)?
- For example, how has your accumulated ability to ensure accurate sampling times and method performance enabled you to confidently execute analytical steps for gentamicin or vancomycin during a DOPS assessment?
- How has reflecting back on this activity shaped your current approach to identifying results that are beyond your scope of practice or require escalation?
- Do you now routinely seek advice from the Pharmacy team or a Senior Clinical Scientist when complex drug interactions or pharmacogenetic factors are suspected of influencing a methotrexate level?
- Looking holistically at your training journey, how has this foundational experience supported your development in meeting the learning outcomes related to applying appropriate investigative strategies and understanding the legal consequences of drug testing?
- In what way does this experience now allow you to contribute effectively to clinical scenarios where toxicology results are used to guide patient management?
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 1 |
Outcome
Analyse drugs, vitamins and trace elements in various biological matrices via quantitative and qualitative assays using automated and manual methodologies. |
| # 2 |
Outcome
Apply the appropriate investigative strategy to clinical situations which may involve drugs or poisons, advising clinical teams on the appropriate course of action. |
| # 5 |
Outcome
Demonstrate the application of pharmacokinetics and pharmacogenomics in therapeutic drug monitoring. |
| # 6 |
Outcome
Illustrate how toxicology results are used in clinical practice and the legal consequences of drug testing in various settings. |